The management of chronic prostatitis in men with HIV

• Published in: Current urology reports 2006-07, Vol.7 (4), p.313-319
• Main Authors: Santillo, Vincent M, Lowe, Franklin C
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-Antagonists - therapeutic use; Algorithms; Antiretroviral Therapy, Highly Active; Chronic Disease; Comorbidity; Cystoscopy; HIV Infections - drug therapy; HIV Infections - epidemiology; Humans; Male; Pelvic Pain - etiology; Prostatitis - diagnosis; Prostatitis - epidemiology; Prostatitis - microbiology; Prostatitis - physiopathology; Quercetin - therapeutic use; Quinazolines - therapeutic use; Sulfonamides - therapeutic use; Urodynamics
• ISSN: 1527-2737; 1534-6285
• DOI: 10.1007/s11934-996-0011-3

Prostatitis is a common urologic diagnosis. Although treatment algorithms are available for this poorly understood entity, several adaptations must be made in order to accommodate the therapeutic needs of HIV-positive patients. The most important consideration when treating HIV-infected patients for prostatitis is their current immune status, whether they are immunocompromised or not (non-progressive disease or reconstituted with highly active antiretroviral therapy). A treatment algorithm for those with chronic bacterial prostatitis (Category II), chronic nonbacterial prostatitis (Category IIIA), and prostatodynia (Category IIIB) is presented in this article. In the HIV-positive patient population, there is a greater likelihood for atypical pathogens including fungi, tuberculosis, anaerobes, and viruses. Because the HIV-infected patient is at increased risk for the development of prostatic abscess and urosepsis than the general population, increased monitoring and evaluation and longer-term appropriately directed antimicrobial therapy are required.